The DOI matches its OpenAlex record; 1 of the 1 references it cites were found in a registry or an index.
Ten-Year Follow-Up Results of Transsphenoidal Microsurgery in Acromegaly
Open accessAbstract
Fifty-nine acromegalic patients, transsphenoidally operated by a single neurosurgeon (H.v.D.) were followed for at least 10 yr to assess the late outcome of surgery. Mean follow-up was 16 +/- 0.4 yr (range, 10-22). Criteria for remission were a serum GH concentration below 2.5 microg/L, a normal glucose-suppressed GH (oral glucose tolerance test), and a normal serum insulin-like growth factor I (IGF-I) concentration. Mean serum GH concentration decreased from 59 +/- 8.7 microg/L to 5.6 +/- 1.4 microg/L after surgery. Early postoperative remission rates were 61% (GH, <2.5 microg/L), 67% (suppressed GH), and 60% (both GH <2.5 microg/L and suppressed GH). Early postoperative remission was significantly related to preoperative serum GH concentration (P: = 0.023), but not to tumor size. Of 36 patients with postoperative remission (GH, <2.5 microg/L), 9 patients received (prophylactic) radiotherapy for persistent paradoxical reaction to TRH or probable invasive tumor growth. All nine patients are in remission at the end of follow-up. Of the other 27 patients with postoperative remission, 5 (19%) developed recurrence, becoming evident within 5 yr in 4 patients and after 10 yr in 1 patient. Of these 27 patients, surgical remission rates at the end of follow-up are 78% (random GH, <2.5 microg/L), 73% (normal glucose-suppressed GH), 74% (normal IGF-I), and 65% (normal IGF-I and GH suppression). Of the patients with postoperative persistent disease, 18 patients were irradiated and 5 patients were followed without further treatment. Two of five nontreated patients had spontaneous normalization of GH concentration at the 6 months visit and remained in remission by surgery only. The long-term efficacy of multimodality treatment was evaluated after exclusion of the prophylactically irradiated patients. At the end of follow-up, 48% of patients had not required adjuvant therapy and the rest received radiotherapy (34%), octreotide (10%), or both (8%). Remission rates of multimodality therapy were 96% (serum GH, <2.5 microg/L) and 94% (normal serum IGF-I concentration). Remission rates of transsphenoidal surgery alone were 46% (serum GH, <2.5 microg/L), 44% (normal IGF-I concentration), 41% (suppressed serum GH), and 37% (normal serum IGF-I and suppressed GH). In this first report on separate 10 or more years results of transsphenoidal surgery for acromegaly, using strict criteria for remission, 19% of patients with postoperative remission developed recurrence. Nevertheless, about 40% of patients remain in remission after only surgical intervention, even after a mean follow-up of 16 yr.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience
Ahmed, Elsheikh, Stratton, Page, Adams, & Wass (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00760.x · Cited by 291
Cited by
Mestron, A., Webb, S., Astorga, R., Benito, P., Catala, M., Gaztambide, S., Gomez, J., Halperin, I., Lucas-Morante, T., Moreno, B., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510439 · Cited by 387
Roelfsema, F., Biermasz, N. R., & Pereira, A. M. (2012) · Pituitary · doi:10.1007/s11102-011-0347-7 · Cited by 346
Self-citationResults of Transsphenoidal Surgery in a Large Series of Patients with Pituitary Adenoma
Mortini, P., Losa, M., Barzaghi, R., Boari, N., & Giovanelli, M. (2005) · Neurosurgery · doi:10.1227/01.neu.0000159647.64275.9d · Cited by 305
Long‐term outcome and mortality after transsphenoidal adenomectomy for acromegaly
Beauregard, C., Truong, U., Hardy, J., & Serri, O. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01679.x · Cited by 300
Biermasz, N. R., van Thiel, S. W., Pereira, A. M., Hoftijzer, H. C., van Hemert, A. M., Smit, J. W. A., Romijn, J. A., & Roelfsema, F. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0669 · Cited by 254
Self-citation
Metadata
- Authors
- Biermasz, N. R., Dulken, H. V., & Roelfsema, F.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- Oxford University Press
- Published
- 2000-12-01
- Volume
- 85
- Issue
- 12
- Pages
- 4596-4602
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2061729174
- Cited by
- 181
- References
- 1
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.